Blood pressure drug recalled after failed test
The U.S. Food and Drug Administration (FDA) has shared details about a new Class II recall for a popular prescription heart medication. The recall was put in place due to a failed Organic Impurities Test.
According to the FDA, this recall involves 675 bottles of 20-mg Enalapril Maleate Tablets manufactured by Unique Pharmaceutical Laboratories, a division of J.B. Chemicals & Pharmaceuticals in India. The bottles were distributed throughout the United States by New Jersey-based Rising Pharma Holdings. They expire on June 30, 2027.
Each bottle contains 1,000 tablets of enalapril maleate, a common ACE inhibitor prescribed to lower a patient’s blood pressure. It can also be used in combination with other medications to treat congestive heart failure. The most well-known version of enalapril maleate is sold and marketed under the brand name Vasotec.
This is a Class II recall, which means the FDA believes exposure “may cause temporary or medically reversible adverse health consequences.” The recall was first initiated by J.B. Chemicals & Pharmaceuticals on April 23. At this time, no patient injuries have been linked to this issue.
Click here for additional details. Read about other recent blood pressure drug recalls here and here.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.